Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 1550

Next Previous
X
Search
Drug Profile

GTB 1550

Alternative Names: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein; DT-2219ARL; DT2219; IND100780; OXS 1550

Latest Information Update: 08 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer Oxis Biotech; University of Minnesota
  • Class ADP ribose transferases; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported B-cell lymphoma; Leukaemia

Most Recent Events

  • 08 Oct 2021 No development reported - Phase-II for B-cell lymphoma (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV)
  • 08 Oct 2021 No development reported - Phase-II for Leukaemia (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV)
  • 28 Sep 2021 No recent reports of development identified for clinical-Phase-Unknown development in B-cell lymphoma(Combination therapy) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top